Gilteritinib (ASP2215) is a potent inhibitor of FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preclinical studies, gilteritinib demonstrated strong antileukemic and antitumor effects. Gilteritinib is currently in several Phase 3 clinical trials for acute myeloid leukemia.
Molecular Weight:
552.71
Purity:
97.75%
CAS Number:
[1254053-43-4]
Formula:
C29H44N8O3
Target:
FLT|||TAM Receptor|||c-Kit
T4409
* VAT and and shipping costs not included. Errors and price changes excepted
